KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Long-Term Debt Repayments: 2019-2021

Historic Long-Term Debt Repayments for AbCellera Biologics (ABCL) over the last 3 years, with Dec 2021 value amounting to $1.8 million.

  • AbCellera Biologics' Long-Term Debt Repayments rose 272.58% to $107,000 in Q2 2021 from the same period last year, while for Jun 2021 it was $19.8 million, marking a year-over-year change of. This contributed to the annual value of $1.8 million for FY2021, which is 90.86% down from last year.
  • Latest data reveals that AbCellera Biologics reported Long-Term Debt Repayments of $1.8 million as of FY2021, which was down 90.86% from $19.9 million recorded in FY2020.
  • AbCellera Biologics' 5-year Long-Term Debt Repayments high stood at $19.9 million for FY2020, and its period low was $399,000 during FY2019.
  • In the last 3 years, AbCellera Biologics' Long-Term Debt Repayments had a median value of $1.8 million in 2021 and averaged $7.4 million.
  • In the last 5 years, AbCellera Biologics' Long-Term Debt Repayments soared by 4,897.99% in 2020 and then plummeted by 90.86% in 2021.
  • AbCellera Biologics' Long-Term Debt Repayments (Yearly) stood at $399,000 in 2019, then surged by 4,897.99% to $19.9 million in 2020, then plummeted by 90.86% to $1.8 million in 2021.